Skip to Content
Merck
  • A dynamic study on reversal of multidrug resistance by ginsenoside Rh₂ in adriamycin-resistant human breast cancer MCF-7 cells.

A dynamic study on reversal of multidrug resistance by ginsenoside Rh₂ in adriamycin-resistant human breast cancer MCF-7 cells.

Talanta (2012-01-24)
Bei Zhou, Xiuli Xiao, Lili Xu, Lian Zhu, Liang Tan, Hao Tang, Youyu Zhang, Qingji Xie, Shouzhuo Yao
ABSTRACT

The quartz crystal microbalance (QCM) dynamic measurements indicate that ginsenoside Rh(2) (G-Rh(2)) could inhibit the proliferation of adriamycin-resistant human breast cancer MCF-7 cells (MCF-7/ADR) in a concentration-dependent way. The combined treatment of G-Rh(2) with adriamycin (ADR) at non-effect dosage resulted in the higher inhibition efficiencies and the increased cell-death velocity, suggesting excellent ability of G-Rh(2) for reversal of multidrug resistance in MCF-7/ADR cells. The cytotoxic effect of the ADR-G-Rh(2) combination was evaluated with the modified Bürgi formula (Jin equation) based on the QCM responses. It presented apparent synergism, indicating the potential ability of G-Rh(2) in tumor therapy. Fluorescent microscopic inspection and methyl thiazolyl tetrazolium (MTT) assay were also carried out and exhibited the comparable results to QCM analysis. The present work may lay an experimental foundation for the application of ginsenosides in cancer therapy, especial in multidrug resistance research.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ginsenoside Rh2, analytical standard